5月25日，据CDE官网消息，普米斯生物技术（珠海）有限公司联合申请药品“PM1032注射液”，获得临床试验默示许可，受理号CXSB2500025。
公示信息显示，药品“PM1032注射液”适应症：胃癌、食管癌、胰腺癌等晚期恶性实体瘤。
普米斯生物技术（珠海）有限公司，成立于2018年，位于珠海市，是一家以从事研究和试验发展为主的企业。企业注册资本14399.40231万美元，实缴资本11500万美元。
通过天眼查大数据分析，普米斯生物技术（珠海）有限公司共对外投资了3家企业，参与招投标项目2次，知识产权方面有商标信息16条，专利信息50条，此外企业还拥有行政许可24个。
主要股东信息显示，普米斯生物技术（珠海）有限公司由Biotheus (HongKong) Limited持股100%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.